The CDTI Innovation invests, together with SABADELL ASABYS HEALTH INNOVATION INVESTMENTS II, RCF and SABADELL ASABYS HEALTH INNOVATION INVESTMENTS 2B, SCR SA, QUIBIM, S.L., company biomedical technology

Quibimleading company in health technology and pioneer in the transformation of medicine as precision machining using biomarkers of image, announced the closure of its funding round Number for a total of 50 million. The round was led byAsabysthrough its merits Sabadell Asabys II, and Buenavista Equity Partners, through the BHG I, created in partnership with Columbus Venture Partners, with the participation of new investors as UI Investissements and GoHub Ventures, in addition to current investors in Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund fund) and Build Collective, Tony Fadell. Between prominent individual investors is dr. Jonathan Milner, founder of Abcam plc —

Quibimworks with the ambitious aim to understand what is happening in each of the tissues of the human body, at any time and a noninvasive. To achieve this, the company develops models of IA applied to medical image to extract useful information from mri (RM), assessed (TC) and ct emission positrons (PET). These developments can characterize the phenotype results and to predict accurately in Clinical oncology, as the immunology, neuroscience and study of metabolic disorders.

A viewer prostate RM einforme structured to atlas of the prostate, with the presence of an injury.

With the financing of the Series A,Quibimconsolidates a strong presence in united states, following its success in europe, through strategic partnerships with hospitals and pharmaceutical companies. In line with its strategic plan and building on its range of solutions authorized by the FDA, the company will support to hospitals and clinical researchers in the efficient processing of large volumes of data from medical imaging. In Addition, the image solutions IA drivenQuibimwill allow pharmaceutical companies to significantly improve the effectiveness of their clinical trials and accelerate the development of drugs, providing useful and accurate information derived from biomarkers of image.

QUIBIM

Quibimit is a health technology company pioneer in the development of tools that extract and processed information hides in medical imaging for improving clinical outcomes for patients.Quibimit is at the forefront of research of biomarkers of image in life sciences, encouraging the development of advanced algorithms that convert the image data indictable predictions in oncology, immunology and neurology. The company uses the capabilities of the magnetic resonance imaging (MRI), computerized tomography (CT) and emission positrons (PET) to create medical devices, integrated perfectly into the flows of care providers around the world.

More than 170 health institutions, research centres, hospitals and clinics Quibim use throughout the world. In addition,Quibimcollaborates with Merck KGaA in the development of models of biomarkers of image you predict the response of oncological patients to allergies and inspiring decisions in their overall efforts of new drugs, as well as with Philips in the launching of image solutions and generates reports based on IA for prostate cancer.
Quibimhas offices in new York (USA), Cambridge (Uk), Valencia, Madrid and Barcelona (España).

ASABYS PARTNERS

Asabys Partnersit is a venture capital firm specialized in the health sector, founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs Alantra owned, and with the support of Banc Sabadell as anchor. Asabys investor invests in innovative companies and disruptive covering medical needs not covered in the vertical biofarma and health. Investment in the company comes from their vehicles Sabadell Asabys Health Innovation Investments II, RCF and Sabadell Asabys Health Innovation Investments 2B, SCR SA.

CDTI Innovation

TheCDTI Innovationit is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.

Additionally, through the initiativeInnvierte Economía Sostenible, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.

More information:

Office of the press
prensa@cdti.es
91-581.55.00

On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/29815
X:https :// twitter.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial

This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (@CDTI _ innovation).